Literature DB >> 28024842

Congenital myasthenic syndrome in Israel: Genetic and clinical characterization.

Sharon Aharoni1, Menachem Sadeh2, Yehuda Shapira3, Simon Edvardson3, Muhannad Daana3, Talia Dor-Wollman3, Aviva Mimouni-Bloch4, Ayelet Halevy5, Rony Cohen5, Liora Sagie6, Zohar Argov7, Malcolm Rabie5, Ronen Spiegel8, Ilana Chervinsky8, Naama Orenstein9, Andrew G Engel10, Yoram Nevo5.   

Abstract

The objective of the study was to evaluate the epidemiology of patients with congenital myasthenic syndrome (CMS) in Israel. Targeted mutation analysis was performed based on the clinical symptoms and electrophysiological findings for known CMS. Additional specific tests were performed in patients of Iranian and/or Iraqi Jewish origin. All medical records were reviewed and clinical data, genetic mutations and outcomes were recorded. Forty-five patients with genetic mutations in known CMS genes from 35 families were identified. Mutations in RAPSN were identified in 13 kinships in Israel. The most common mutation was c.-38A>G detected in 8 patients of Iranian and/or Iraqi Jewish origin. Four different recessive mutations in COLQ were identified in 11 kinships, 10 of which were of Muslim-Arab descent. Mutations in CHRNE were identified in 7 kinships. Less commonly detected mutations were in CHRND, CHAT, GFPT1 and DOK7. In conclusion, mutations in RAPSN and COLQ are the most common causes of CMS in our cohort. Specific mutations in COLQ, RAPSN, and CHRNE occur in specific ethnic populations and should be taken into account when the diagnosis of a CMS is suspected.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CHRNE; COLQ; Congenital myasthenic syndrome (CMS); Genetic mutations; RAPSN

Mesh:

Substances:

Year:  2016        PMID: 28024842      PMCID: PMC5280189          DOI: 10.1016/j.nmd.2016.11.014

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  25 in total

1.  Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia.

Authors:  Teerin Liewluck; Duygu Selcen; Andrew G Engel
Journal:  Muscle Nerve       Date:  2011-09-23       Impact factor: 3.217

2.  End-plate acetylcholine receptor deficiency due to nonsense mutations in the epsilon subunit.

Authors:  A G Engel; K Ohno; C Bouzat; S M Sine; R C Griggs
Journal:  Ann Neurol       Date:  1996-11       Impact factor: 10.422

3.  A common mutation (epsilon1267delG) in congenital myasthenic patients of Gypsy ethnic origin.

Authors:  A Abicht; R Stucka; V Karcagi; A Herczegfalvi; R Horváth; W Mortier; U Schara; V Ramaekers; W Jost; J Brunner; G Janssen; U Seidel; B Schlotter; W Müller-Felber; D Pongratz; R Rüdel; H Lochmüller
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

4.  Molecular characterisation of congenital myasthenic syndromes in Southern Brazil.

Authors:  V Mihaylova; R H Scola; B Gervini; P J Lorenzoni; C K Kay; L C Werneck; R Stucka; V Guergueltcheva; M von der Hagen; A Huebner; A Abicht; J S Müller; H Lochmüller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-06-20       Impact factor: 10.154

5.  Three novel COLQ mutations and variation of phenotypic expressivity due to G240X.

Authors:  Y A Shapira; M E Sadeh; M P Bergtraum; A Tsujino; K Ohno; X M Shen; J Brengman; S Edwardson; I Matoth; A G Engel
Journal:  Neurology       Date:  2002-02-26       Impact factor: 9.910

6.  Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme.

Authors:  K Ohno; J Brengman; A Tsujino; A G Engel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

7.  Congenital myasthenic syndromes in childhood: diagnostic and management challenges.

Authors:  M Kinali; D Beeson; M C Pitt; H Jungbluth; A K Simonds; A Aloysius; H Cockerill; T Davis; J Palace; A Y Manzur; C Jimenez-Mallebrera; C Sewry; F Muntoni; S A Robb
Journal:  J Neuroimmunol       Date:  2008-08-15       Impact factor: 3.478

Review 8.  The therapy of congenital myasthenic syndromes.

Authors:  Andrew G Engel
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

9.  Clinical features of the DOK7 neuromuscular junction synaptopathy.

Authors:  Jacqueline Palace; Daniel Lashley; John Newsom-Davis; Judy Cossins; Susan Maxwell; Robin Kennett; Sandeep Jayawant; Yuji Yamanashi; David Beeson
Journal:  Brain       Date:  2007-04-23       Impact factor: 13.501

Review 10.  Inherited disorders of the neuromuscular junction: an update.

Authors:  Pedro M Rodríguez Cruz; Jacqueline Palace; David Beeson
Journal:  J Neurol       Date:  2014-10-11       Impact factor: 4.849

View more
  12 in total

1.  Incidence and Ocular Features of Pediatric Myasthenias.

Authors:  Sasha A Mansukhani; Erick D Bothun; Nancy N Diehl; Brian G Mohney
Journal:  Am J Ophthalmol       Date:  2019-01-14       Impact factor: 5.258

2.  Genetic Landscape of Congenital Myasthenic Syndromes From Turkey: Novel Mutations and Clinical Insights.

Authors:  Uluç Yiş; Kerstin Becker; Semra Hız Kurul; Gökhan Uyanik; Erhan Bayram; Göknur Haliloğlu; Ayşe İpek Polat; Müge Ayanoğlu; Derya Okur; Ayşe Fahriye Tosun; Gül Serdaroğlu; Sanem Yilmaz; Haluk Topaloğlu; Banu Anlar; Sebahattin Cirak; Andrew G Engel
Journal:  J Child Neurol       Date:  2017-05-03       Impact factor: 1.987

3.  Congenital myasthenic syndromes in Turkey: Clinical clues and prognosis with long term follow-up.

Authors:  Hacer Durmus; Xin-Ming Shen; Piraye Serdaroglu-Oflazer; Bulent Kara; Yesim Parman-Gulsen; Coskun Ozdemir; Joan Brengman; Feza Deymeer; Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2017-11-28       Impact factor: 4.296

4.  A common CHRNE mutation in Brazilian patients with congenital myasthenic syndrome.

Authors:  Eduardo de Paula Estephan; Cláudia Ferreira da Rosa Sobreira; André Clériston José Dos Santos; Pedro José Tomaselli; Wilson Marques; Roberta Paiva Magalhães Ortega; Marcela Câmara Machado Costa; André Macedo Serafim da Silva; Rodrigo Holanda Mendonça; Vitor Marques Caldas; Antonio Alberto Zambon; Osório Abath Neto; Paulo Eurípedes Marchiori; Carlos Otto Heise; Umbertina Conti Reed; Yoshiteru Azuma; Ana Töpf; Hanns Lochmüller; Edmar Zanoteli
Journal:  J Neurol       Date:  2018-01-30       Impact factor: 4.849

5.  Homozygous mutations in VAMP1 cause a presynaptic congenital myasthenic syndrome.

Authors:  Vincenzo Salpietro; Weichun Lin; Andrea Delle Vedove; Markus Storbeck; Yun Liu; Stephanie Efthymiou; Andreea Manole; Sarah Wiethoff; Qiaohong Ye; Anand Saggar; Kenneth McElreavey; Shyam S Krishnakumar; Matthew Pitt; Oscar D Bello; James E Rothman; Lina Basel-Vanagaite; Monika Weisz Hubshman; Sharon Aharoni; Adnan Y Manzur; Brunhilde Wirth; Henry Houlden
Journal:  Ann Neurol       Date:  2017-03-29       Impact factor: 10.422

6.  CHRNE compound heterozygous mutations in congenital myasthenic syndrome: A case report.

Authors:  Kunfang Yang; Hongyi Cheng; Fang Yuan; Linyi Meng; Rongrong Yin; Yuanfeng Zhang; Simei Wang; Chunmei Wang; Yanfen Lu; Jiaming Xi; Qin Lu; Yucai Chen
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

7.  Congenital myasthenic syndromes.

Authors:  Josef Finsterer
Journal:  Orphanet J Rare Dis       Date:  2019-02-26       Impact factor: 4.123

8.  No Hot Spot Mutations CHRNE c.1327 delG, CHAT c.914T>C, and RAPSN c.264C>A in Iranian Patients with Congenital Myasthenic Syndrome.

Authors:  Sima Parvizi Omran; Massod Houshmand; Donkor Dominic; Zahra Farjami; Parvaneh Karimzadeh
Journal:  Iran J Child Neurol       Date:  2019

9.  Congenital myasthenic syndrome in China: genetic and myopathological characterization.

Authors:  Yawen Zhao; Ying Li; Yang Bian; Sheng Yao; Penju Liu; Meng Yu; Wei Zhang; Zhaoxia Wang; Yun Yuan
Journal:  Ann Clin Transl Neurol       Date:  2021-03-23       Impact factor: 4.511

10.  New compound heterozygous variants of the cholinergic receptor nicotinic delta subunit gene in a Chinese male with congenital myasthenic syndrome: A case report.

Authors:  Huiru Feng; Hongyu Zhou
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.